Nubeqa Europska Unija - hrvatski - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - tumori prostate, Кастраци-uporan - endokrinska terapija - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Adempas Europska Unija - hrvatski - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hipertenzija, plućna - antihipertenzivi za plućnu arterijsku hipertenziju - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitost je dokazana u populaciji uh uključujući etiologija idiopatskom ili nasljedne ili uh uh, povezane s bolestima vezivnog tkiva . paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Oyavas Europska Unija - hrvatski - EMA (European Medicines Agency)

oyavas

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Xofigo Europska Unija - hrvatski - EMA (European Medicines Agency)

xofigo

bayer ag - radium (223ra) dichloride - prostatske neoplazme - terapeutski radiofarmaceutski pripravci - xofigo je indiciran za liječenje odraslih osoba s karcinomom prostate otpornih na kastriranje, simptomatskim koštanim metastazama i bez poznatih visceralnih metastaza.

LERCANIL ACE 10 mg/1 tableta+ 10 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lercanil ace 10 mg/1 tableta+ 10 mg/1 tableta film tableta

berlin chemie / menarini bh d.o.o. sarajevo - enalapril, lerkanidipin - film tableta - 10 mg/1 tableta+ 10 mg/1 tableta - 1 film tableta sadrži: 10 mg enalaprilmaleata 10 mg lerkanidipinhidrohlorida

LERCANIL ACE 20 mg/1 tableta+ 10 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lercanil ace 20 mg/1 tableta+ 10 mg/1 tableta film tableta

berlin chemie / menarini bh d.o.o. sarajevo - enalapril, lerkanidipin - film tableta - 20 mg/1 tableta+ 10 mg/1 tableta - 1 film tableta sadrži: 20 mg enalaprilmaleata 10 mg lerkanidipinhidrohlorida

LERCANIL ACE 20 mg/1 tableta+ 10 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lercanil ace 20 mg/1 tableta+ 10 mg/1 tableta film tableta

berlin chemie / menarini bh d.o.o. sarajevo - enalapril, lerkanidipin - film tableta - 20 mg/1 tableta+ 10 mg/1 tableta - 1 film tableta sadrži: 20 mg enalaprilmaleata i 10 mg lerkanidipinhidrohlorida